E-pharmacies claim in HC they are like Swiggy, only deliver drugs

Image
Press Trust of India New Delhi
Last Updated : Jul 04 2019 | 3:55 PM IST

E-pharmacies on Thursday told the Delhi High Court that they do not require a license for online sale of drugs and prescription medicines as they do not sell them, instead they are only delivering the medications akin to food-delivery app Swiggy.

The e-pharmacies told a bench of Chief Justice D N Patel and Justice C Hari Shankar that just like Swiggy does not require a restaurant license to deliver food, they do not require any license to deliver medicines to customers who purchase drugs online.

The submission came during hearing of a plea seeking contempt action against the e-pharmacies for continuing to sell drugs online despite a high court order staying such activity.

The petition also seeks contempt action against the central government for allegedly not taking any action against the defaulting e-pharmacies.

The central government, in its defense, told the court that framing of rules to regulate e-pharmacies was under consideration and consultations were being held with all the stakeholders.

Several of the e-pharmacy companies and the Centre also sought time to file their response to the contempt plea.

Subsequently, the bench granted them time till September 24, the next date of hearing.

The contempt plea was filed by Zaheer Ahmed who had earlier moved a PIL seeking a ban on "illegal" sale of drugs online.

The high court had earlier stayed the sale of drugs and prescription medicines by online pharmacies while hearing Ahmed's PIL.

In his earlier petition, he has said that the online illegal sale of medicines would lead to a drug epidemic, drug abuse and misutilisation of habit forming and addictive drugs.

The PIL has said that since there was no mechanism to control the sale of medicines online, this puts health and lives of people at a high risk and affects their right to a safe and healthy life under Article 21 of the Constitution.

"Online pharmacies are operating without a drug licence and cannot be regulated in the present regime. Unregulated and unlicensed sale of medicines will increase risk of spurious, misbranded and sub-standard drugs being sold," the plea has said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 04 2019 | 3:55 PM IST

Next Story